At the ARVO meeting in Seattle, Eye2Gene and Heidelberg Engineering announced a collaborative partnership. By combining Eye2Gene’s artificial intelligence (AI) algorithm with Heidelberg Engineering’s workflow solutions, the partnership aims to advance the care pathway for patients with inherited retinal disease, Heidelberg stated in a press release.

Attendees at ARVO saw a joint demonstration that showcased the integration of Eye2Gene’s AI algorithm for the prediction of inherited retinal disease genes using SPECTRALIS BluePeak autofluorescence, confocal scanning laser ophthalmoscope infrared and OCT images with HEYEX 2’s Heidelberg AppWay. 

In addition, researchers had the opportunity to learn how images acquired with the SPECTRALIS can be interrogated by Eye2Gene to predict which gene is causing the inherited disease, offering a glimpse into the future of precision medicine in ophthalmology.

The Eye2Gene research project team presented two posters at ARVO detailing the science behind the solution.